AMAG Pharmaceuticals Earnings: Here’s Why Investors Like These Results
AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) had a loss and beat Wall Street’s expectations, AND met the revenue expectation. The revenue miss is a negative sign to shareholders seeking high growth out of the company. Shares are up 3.72%.
AMAG Pharmaceuticals, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased to $-0.18 in the quarter versus EPS of $-0.58 in the year-earlier quarter.
Revenue: Rose 15.63% to $17.9 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: AMAG Pharmaceuticals, Inc. reported adjusted EPS loss of $0.18 per share. By that measure, the company beat the mean analyst estimate of $-0.21. It met the average revenue estimate of $17.9 million.
Quoting Management: “We have gotten off to a very strong start in 2013, delivering record results through a combination of solid top-line growth and disciplined financial management,” said William Heiden, president and chief executive officer of AMAG. “In the first quarter, we achieved our largest volume of non-dialysis Feraheme sales since launch. Our new chief commercial officer, Greg Madison, and his team did an excellent job of driving Feraheme performance this quarter, achieving especially strong growth in the largest segment of the non-dialysis IV iron market, the hospital segment.”
Key Stats (on next page)…